- Home
- RNAC vs IMRX Comparison
RNAC vs IMRX Comparison
Compare RNAC & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAC
- IMRX
- Stock Information
- Founded
- RNAC 2007
- IMRX 2008
- Country
- RNAC United States
- IMRX United States
- Employees
- RNAC N/A
- IMRX N/A
- Industry
- RNAC Biotechnology: Pharmaceutical Preparations
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- RNAC Health Care
- IMRX Health Care
- Exchange
- RNAC Nasdaq
- IMRX Nasdaq
- Market Cap
- RNAC 204.6M
- IMRX 232.9M
- IPO Year
- RNAC 2016
- IMRX 2021
- Fundamental
- Price
- RNAC $7.49
- IMRX $6.23
- Analyst Decision
- RNAC Strong Buy
- IMRX Strong Buy
- Analyst Count
- RNAC 4
- IMRX 5
- Target Price
- RNAC $40.50
- IMRX $17.20
- AVG Volume (30 Days)
- RNAC 154.5K
- IMRX 1.2M
- Earning Date
- RNAC 11-06-2025
- IMRX 11-12-2025
- Dividend Yield
- RNAC N/A
- IMRX N/A
- EPS Growth
- RNAC N/A
- IMRX N/A
- EPS
- RNAC N/A
- IMRX N/A
- Revenue
- RNAC $1,091,000.00
- IMRX N/A
- Revenue This Year
- RNAC N/A
- IMRX N/A
- Revenue Next Year
- RNAC N/A
- IMRX N/A
- P/E Ratio
- RNAC N/A
- IMRX N/A
- Revenue Growth
- RNAC N/A
- IMRX N/A
- 52 Week Low
- RNAC $5.98
- IMRX $1.10
- 52 Week High
- RNAC $26.50
- IMRX $10.08
- Technical
- Relative Strength Index (RSI)
- RNAC 36.81
- IMRX 48.81
- Support Level
- RNAC $7.15
- IMRX $5.98
- Resistance Level
- RNAC $7.74
- IMRX $7.57
- Average True Range (ATR)
- RNAC 0.66
- IMRX 0.59
- MACD
- RNAC -0.02
- IMRX 0.01
- Stochastic Oscillator
- RNAC 50.87
- IMRX 23.27
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.